Yang Hai-Qing, Qiu Fa-Qi, Jin K E, Jiang Neng-Gang, Zhang L I
Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China.
Department of Clinical Laboratories, Ministry of Health, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Exp Ther Med. 2015 Jun;9(6):2394-2400. doi: 10.3892/etm.2015.2392. Epub 2015 Mar 27.
Dyslipidemia is a common feature in immunosuppressed patients, such as kidney and bone marrow transplantation recipients and patients with breast, prostate or gynecological carcinoma or acute lymphoblastic leukemia. In addition, high levels of oxidatively modified low-density lipoproteins (oxLDLs) are closely associated with carcinogenesis. There are, however, no reports on the association between the serum oxLDL levels and the expression of important immunomodulatory molecules in patients with hematological disorders. In the present study, 39 patients with hematological disorders were stratified into four groups: Two groups with malignancies [chronic myeloid leukemia (CML) and acute myeloblastic leukemia (AML)] and two groups without malignancies [myelodysplastic syndrome (MDS) and iron deficiency anemia (IDA)]. Immunomodulatory molecules were monitored in these groups. The enzyme-linked immunosorbent assay results indicated that the plasma oxLDL levels were significantly higher in patients with AML or CML than those in patients with MDS or IDA. The quantitative polymerase chain reaction results revealed that the expression of numerous important immunomodulatory elements, including tumor-related genes, immunological and inflammatory cytokines, defense-responsive genes, genes regulating cell proliferation, adhesion and migration molecules and leukocyte chemotaxis genes, showed considerable variation in patients with hematological disorders, particularly in those with MDS or IDA, as compared with the expression in the healthy volunteers. The present study demonstrated that, in patients with a hematological malignancy (either AML or CML), the activation of numerous immune response-related molecules was inhibited. Thus, an association between hematological malignancies and dyslipidemia, i.e. high levels of oxLDL, is suggested. Further research is necessary to investigate how oxLDL influences cancer progression.
血脂异常是免疫抑制患者的常见特征，如肾和骨髓移植受者以及患有乳腺癌、前列腺癌或妇科癌症或急性淋巴细胞白血病的患者。此外，高水平的氧化修饰低密度脂蛋白（oxLDL）与致癌作用密切相关。然而，关于血液系统疾病患者血清oxLDL水平与重要免疫调节分子表达之间的关联尚无报道。在本研究中，39例血液系统疾病患者被分为四组：两组患有恶性肿瘤[慢性髓性白血病（CML）和急性髓性白血病（AML）]，两组未患恶性肿瘤[骨髓增生异常综合征（MDS）和缺铁性贫血（IDA）]。对这些组中的免疫调节分子进行了监测。酶联免疫吸附测定结果表明，AML或CML患者的血浆oxLDL水平显著高于MDS或IDA患者。定量聚合酶链反应结果显示，与健康志愿者相比，许多重要的免疫调节元件的表达在血液系统疾病患者中，特别是在MDS或IDA患者中，表现出相当大的差异，这些元件包括肿瘤相关基因、免疫和炎性细胞因子、防御反应基因、调节细胞增殖、黏附和迁移分子的基因以及白细胞趋化基因。本研究表明，在患有血液系统恶性肿瘤（AML或CML）的患者中，许多免疫反应相关分子的激活受到抑制。因此，提示血液系统恶性肿瘤与血脂异常（即高水平的oxLDL）之间存在关联。有必要进一步研究oxLDL如何影响癌症进展。
